Is CNIVF or MRK a better dividend investment in 2026?

CNIVF currently yields 449.44% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: CNIVF offers higher current income.

What is the dividend yield difference between CNIVF and MRK?

CNIVF has a forward dividend yield of 449.44% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 446.68 percentage points.

Home › Compare › CNIVF vs MRK

CNIVF vs MRK: Dividend Comparison 2026

CNIVF yields 449.44% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CNIVF wins by $199.4K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CNIVF

● Live price

449.44%

Share price

$0.45

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$256.2K

Annual income

$570.39

Full CNIVF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — CNIVF vs MRK

📍 CNIVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CNIVF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CNIVF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CNIVF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNIVF

Annual income on $10K today (after 15% tax)

$38,202.25/yr

After 10yr DRIP, annual income (after tax)

$484.83/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, MRK beats the other by $7,843.58/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNIVF + MRK for your $10,000?

CNIVF: 50%MRK: 50%

100% MRK50/50100% CNIVF

Portfolio after 10yr

$156.5K

Annual income

$5,184.27/yr

Blended yield

3.31%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CNIVF

No analyst data

Altman Z

603.0

Piotroski

3/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNIVF buys

MRK buys

No recent congressional trades found for CNIVF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCNIVFMRK

Forward yield	449.44% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	32.7% ✓
Portfolio after 10y	$256.2K ✓	$56.8K
Annual income after 10y	$570.39	$9,798.13 ✓
Total dividends collected	$149.0K ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: CNIVF vs MRK ($10,000, DRIP)

Year	CNIVF Portfolio	CNIVF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$33,172	$22,471.91	$11,206	$366.19	+$22.0K → CNIVF
2	$70,327	$34,833.47	$12,650	$502.35	+$57.7K → CNIVF
3	$109,760	$34,509.37	$14,407	$694.19	+$95.4K → CNIVF
4	$142,610	$25,167.59	$16,585	$967.82	+$126.0K → CNIVF
5	$167,874	$15,280.46	$19,342	$1,363.89	+$148.5K → CNIVF
6	$188,030	$8,405.31	$22,913	$1,947.19	+$165.1K → CNIVF
7	$205,592	$4,399.31	$27,662	$2,823.89	+$177.9K → CNIVF
8	$222,231	$2,247.75	$34,159	$4,173.35	+$188.1K → CNIVF
9	$238,922	$1,135.36	$43,337	$6,308.80	+$195.6K → CNIVF
10	$256,217	$570.39	$56,776	$9,798.13	+$199.4K → CNIVF

CNIVF vs MRK: Complete Analysis 2026

CNIVF — Stock

Carmen Century Investment Ltd. engages in investing in listed and unlisted securities. It operates through the Hong Kong and People's Republic of China geographical segments. The company was founded on September 18, 2001 and is headquartered in Hong Kong.

Full CNIVF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this CNIVF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNIVF vs SCHD CNIVF vs JEPI CNIVF vs O CNIVF vs KO CNIVF vs MAIN CNIVF vs JNJ CNIVF vs ABBV CNIVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.